evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,771 questions · 10,185 findings · 893 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,109 · 20.7%GRADE not reported 1,125 · 11%Very low 2,279 · 22.4%Low 2,514 · 24.7%Moderate 1,709 · 16.8%High 449 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Loratadine 10 mg vs placebo (2‐week intervention)

Secondary outcome 1. Physician‐assessed clinical signs Number for whom treatment success was judged as good or very good · adults with eczema

Loratadine 10 mg/d showed no clear difference in secondary outcome 1. Physician‐assessed clinical signs Number for… compared with placebo (2‐week intervention) (low certainty).

1 finding from 1 review

Cetirizine 10 mg/d vs placebo (4‐week intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma

TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Proportion of participants without serum AFP normalisation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).

1 finding from 1 review

Any antibiotic regimen plus N‐acetylcysteine vs the same regimen without N‐acetylcysteine (with or without placebo)

Eradication rate · patients with Helicobacter pylori infection

It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes eradication rate compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).

1 finding from 1 review

Any antibiotic regimen plus N‐acetylcysteine vs the same regimen without N‐acetylcysteine (with or without placebo)

Gastrointestinal adverse events · patients with Helicobacter pylori infection

It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes gastrointestinal adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).

1 finding from 1 review